tmem216 Antibody

What is TMEM216 and why is it significant for ciliopathy research?

TMEM216 is an evolutionarily conserved tetraspan transmembrane protein that localizes primarily to the base of primary cilia or adjacent basal body in ciliated cells. It plays a critical role in ciliogenesis and proper centrosomal docking at the apical cell surface . The significance of TMEM216 in ciliopathy research stems from its genetic association with Joubert syndrome (JBTS) and Meckel syndrome (MKS), two severe developmental disorders . These conditions represent a spectrum of ciliopathies with TMEM216 mutations identified in both JSRD (Joubert Syndrome and Related Disorders) patients and MKS fetuses . Additionally, recent research has linked TMEM216 variants to recessive retinitis pigmentosa, particularly in individuals of African ethnicity , expanding its relevance to retinal degeneration studies.

The protein's location and function at the ciliary transition zone makes TMEM216 antibodies essential tools for studying the molecular mechanisms underlying ciliopathies and normal cilia function. Investigating TMEM216 provides insights into fundamental cellular processes involving centrosome positioning, ciliogenesis, and regulation of key signaling pathways like RhoA and Dishevelled that influence cell polarity and development .

What subcellular structures can be visualized using TMEM216 antibodies?

TMEM216 antibodies primarily detect structures at the base of primary cilia, including:

• The ciliary transition zone - TMEM216 is a component of the transition zone tectonic complex that regulates protein entry and exit from the cilium .

• The basal body region - TMEM216 shows strong localization at or adjacent to the basal body in ciliated cells .

• Other microtubule structures - Epitope-tagged TMEM216 has been observed localizing to additional microtubule-based structures, including the mitotic spindle in cells undergoing late telophase .

Immunofluorescence techniques using TMEM216 antibodies, particularly when co-stained with markers like acetylated or glutamylated tubulin, allow visualization of these structures in various cell types including inner medullary collecting duct (IMCD3) cells and retinal pigment epithelium (hRPE) cells . The antibodies also react strongly with ciliated cells in tissues such as kidney .

When designing experiments to visualize TMEM216-associated structures, researchers should consider using z-stack confocal microscopy to fully capture the three-dimensional organization of the transition zone and basal body complex. Super-resolution microscopy techniques can provide enhanced detail of TMEM216's precise localization within these substructures.

What validation methods are essential before using a new TMEM216 antibody?

Before employing a new TMEM216 antibody in experiments, researchers should implement the following validation protocols:

• Specificity testing through Western blot analysis:

  • Compare protein detection in control samples versus TMEM216 knockout or knockdown samples

  • Verify the presence of a band at approximately 19 kD, matching the predicted 148 amino acid full-length protein

  • Confirm that this band is attenuated or absent in samples from TMEM216 mutant cells (e.g., p.R85X fibroblasts)

• Immunofluorescence validation:

  • Perform parallel staining of control cells and TMEM216-deficient cells

  • Confirm localization at the base of cilia in control cells

  • Verify absence of specific signal in knockout/knockdown cells or tissues

• Peptide competition assay:

  • Pre-incubate the antibody with the immunizing peptide

  • Confirm that this pre-treatment abolishes specific staining

• Cross-reactivity assessment:

  • Test the antibody in tissues known to express TMEM216 (e.g., retina, kidney, brain)

  • Verify expression pattern matches known TMEM216 distribution from in situ hybridization data

Implementing these validation steps is crucial, as demonstrated in previous research where TMEM216 antibodies raised against amino acids 81-90 showed specific reactivity that was absent in TMEM216 p.R85X homozygous mutant fibroblasts . This methodical approach ensures experimental results accurately reflect TMEM216 biology rather than non-specific binding.

How can TMEM216 antibodies be utilized to investigate ciliogenesis defects?

TMEM216 antibodies offer powerful tools for investigating ciliogenesis defects through several methodological approaches:

• Quantitative analysis of ciliogenesis:

  • Compare ciliation rates between control and experimental conditions using TMEM216 and ciliary markers (acetylated tubulin)

  • Measure cilia length and frequency in cell populations

  • Quantify the percentage of cells with cilia (defined as >1 μm length) versus those without cilia (<1 μm length)

• Centrosome docking analysis:

  • Evaluate centrosome positioning relative to the nucleus using TMEM216 antibodies alongside centrosomal markers

  • Analyze the percentage of cells with centrosomes located apical to the nucleus

  • Track the dynamics of centrosome migration during ciliogenesis

• Study of transition zone formation:

  • Investigate the assembly of transition zone complexes using co-immunoprecipitation with TMEM216 antibodies

  • Examine the recruitment of other transition zone proteins in TMEM216-deficient cells

  • Analyze transition zone ultrastructure using immunogold electron microscopy with TMEM216 antibodies

Previous research has demonstrated that TMEM216 deficiency, either in patient fibroblasts carrying the p.R85X mutation or following siRNA knockdown, causes defective ciliogenesis and improper centrosomal docking . TMEM216 antibodies can help elucidate the molecular mechanisms underlying these defects by identifying mislocalized proteins and disrupted interactions in the absence of functional TMEM216.

What techniques can help investigate TMEM216 protein interactions in ciliary transition zone complexes?

Investigating TMEM216 protein interactions within ciliary transition zone complexes requires sophisticated biochemical and imaging approaches:

• Co-immunoprecipitation (Co-IP) assays:

  • Use TMEM216 antibodies to pull down interacting protein complexes

  • Perform reverse Co-IP with antibodies against suspected interaction partners

  • Analyze complexes by Western blotting or mass spectrometry

• Proximity ligation assays (PLA):

  • Combine antibodies against TMEM216 and potential interaction partners

  • Visualize protein-protein interactions in situ with single-molecule resolution

  • Quantify interaction frequencies in different cellular compartments

• FRET/FLIM imaging with immunolabeled samples:

  • Use fluorescently-tagged secondary antibodies for TMEM216 and interacting proteins

  • Measure energy transfer to confirm physical proximity of protein pairs

  • Map interaction domains within the transition zone

• BioID or APEX2 proximity labeling:

  • Generate TMEM216 fusion constructs with biotin ligase or peroxidase

  • Identify proximal proteins using streptavidin pulldown followed by mass spectrometry

  • Validate interactions using TMEM216 antibodies

Research has established that TMEM216 forms complexes with Meckelin, another transition zone protein encoded by the MKS3/TMEM67 gene also implicated in Joubert and Meckel syndromes . This interaction was confirmed through immunoprecipitation experiments where GFP-tagged TMEM216 was pulled down with antibodies against either N- or C-terminal portions of Meckelin, and the reciprocal experiment showed that TMEM216 could pull down Meckelin .

TMEM216 is also part of the transition zone tectonic complex that includes multiple proteins associated with ciliopathies: TCTN1, TCTN2, TCTN3, TMEM67 (meckelin), B9D1, CEP290, MKS-1, and CC2D2A . Antibody-based methods can help map the organization of these protein modules and determine how TMEM216 mutations affect complex assembly.

How can TMEM216 antibodies be applied to studying retinal pathologies?

TMEM216 antibodies provide valuable research tools for investigating retinal pathologies, particularly given the association between TMEM216 mutations and retinal degeneration:

• Immunohistochemical analysis of retinal layers:

  • Examine TMEM216 distribution across different retinal cell types

  • Compare localization patterns between healthy and diseased retinal tissue

  • Correlate TMEM216 expression with structural markers of photoreceptor health

• Quantitative assessment of protein mislocalization:

  • Investigate the localization of outer segment proteins (rhodopsin, GNAT2, opsins) in TMEM216-deficient photoreceptors

  • Measure the extent of protein mislocalization to inner segments and cell bodies

  • Correlate mislocalization with functional photoreceptor defects

• Analysis of ciliary axoneme structure:

  • Evaluate photoreceptor connecting cilium morphology using TMEM216 antibodies alongside axonemal markers

  • Quantify ciliary axoneme length in control versus TMEM216-deficient photoreceptors

  • Correlate structural abnormalities with visual function

• Investigation of retinal degeneration mechanisms:

  • Monitor photoreceptor apoptosis in relation to TMEM216 expression

  • Quantify TUNEL-positive nuclei in retinal sections

  • Analyze key signaling pathways affected by TMEM216 deficiency

Research in zebrafish models has shown that tmem216 knockout results in shortened photoreceptor ciliary axonemes, mislocalization of outer segment proteins, and abnormal disc morphology in the outer segment . Recent studies have also identified a common TMEM216 variant (c.-69G>T) as a significant cause of recessive retinitis pigmentosa in families of African ethnicity . TMEM216 antibodies can help elucidate the molecular mechanisms connecting these genetic findings to the observed cellular and tissue-level pathologies.

What optimization steps are critical for TMEM216 antibody immunofluorescence in different cell types?

Optimizing TMEM216 antibody immunofluorescence protocols for different cell types requires attention to several critical parameters:

• Fixation method selection:

  • Test multiple fixation protocols (4% paraformaldehyde, methanol, or glutaraldehyde)

  • Optimize fixation duration to preserve antigen accessibility

  • Consider dual fixation methods for simultaneous visualization of membrane and cytoskeletal elements

• Permeabilization optimization:

  • Adjust detergent type and concentration for different cell types

  • For ciliary structures, test Triton X-100 (0.1-0.5%) versus milder detergents like saponin

  • Optimize permeabilization time to prevent epitope damage while ensuring antibody access

• Antibody dilution determination:

  • Perform titration series to identify optimal primary antibody concentration

  • Test different dilutions of secondary antibodies to maximize signal-to-noise ratio

  • Consider signal amplification systems for low-abundance TMEM216 detection

• Antigen retrieval evaluation:

  • Test necessity of antigen retrieval methods for fixed tissue sections

  • Optimize pH and temperature conditions if needed

  • Compare citrate-based versus EDTA-based retrieval solutions

• Blocking optimization:

  • Test different blocking solutions (BSA, normal serum, commercial blockers)

  • Determine optimal blocking duration to minimize background

  • Consider adding detergents to blocking solutions to reduce non-specific binding

Previous research has successfully used TMEM216 antibodies for immunostaining in multiple cell types, including inner medullary collecting duct (IMCD3) cells, retinal pigment epithelium (hRPE) cells, and kidney tissue sections . For ciliary protein detection, it's critical to include appropriate ciliary markers such as acetylated or glutamylated tubulin to accurately identify the base of cilia and basal bodies where TMEM216 localizes .

What methodological approaches resolve contradictory findings about TMEM216 localization?

Resolving contradictory findings about TMEM216 localization requires systematic methodological approaches:

• Multi-antibody validation strategy:

  • Use antibodies targeting different TMEM216 epitopes

  • Compare monoclonal and polyclonal antibodies

  • Validate each antibody against knockout/knockdown controls

• Cell type and condition standardization:

  • Systematically compare TMEM216 localization across different cell types

  • Standardize culture conditions, confluency, and serum starvation protocols

  • Document cell cycle stage effects on TMEM216 distribution

• Epitope tag complementation:

  • Compare native protein localization (antibody-detected) with epitope-tagged versions

  • Use multiple tag positions (N-terminal, C-terminal, internal) to identify tag interference

  • Validate tagged protein functionality through rescue experiments

• Fixation artifact elimination:

  • Compare live-cell imaging of fluorescently tagged TMEM216 with fixed specimens

  • Implement rapid fixation techniques to minimize protein relocalization

  • Use correlative light and electron microscopy to confirm subcellular localization

• Super-resolution microscopy application:

  • Employ techniques like STORM, PALM, or STED for nanoscale resolution

  • Use 3D reconstruction to precisely map TMEM216 relative to ciliary substructures

  • Quantify colocalization coefficients with established markers

Researchers have observed that TMEM216 primarily localizes to the base of the primary cilium or adjacent basal body, with additional localization to structures like the mitotic spindle during cell division . When conflicting results arise, implementing these systematic approaches can help distinguish genuine biological variation from technical artifacts.

What controls are essential for Western blot analysis using TMEM216 antibodies?

Western blot analysis with TMEM216 antibodies requires rigorous controls to ensure reliable and interpretable results:

• Essential positive and negative controls:

  • Positive control: Lysate from cells known to express TMEM216 (e.g., IMCD3 cells)

  • Negative control: Lysate from TMEM216 knockout cells or siRNA knockdown cells

  • Peptide competition control: Pre-incubation of antibody with immunizing peptide

• Loading and transfer controls:

  • Housekeeping protein detection (e.g., β-actin, as used in previous TMEM216 studies)

  • Total protein staining (Ponceau S, SYPRO Ruby) before immunoblotting

  • Ladder verification to confirm expected molecular weight detection

• Sample preparation considerations:

  • Compare different lysis buffers to optimize TMEM216 extraction

  • Test membrane fraction enrichment protocols for this transmembrane protein

  • Evaluate the need for detergents like SDS, Triton X-100, or NP-40

• Quantification approach:

  • Normalize TMEM216 signals to loading controls (e.g., GNAT2:β-actin ratio)

  • Use digital imaging software (e.g., ImageJ) with consistent measurement methods

  • Apply appropriate statistical analysis for comparing expression levels

Previous research has demonstrated that Western analysis of whole cell lysates from control fibroblasts identifies a band at 19 kD for TMEM216, matching the predicted 148 amino acid full-length protein . This band is attenuated or lost in TMEM216 p.R85X fibroblasts or in IMCD3 cells in which Tmem216 was knocked down . Some TMEM216 mutations lead to unstable protein when transfected into heterologous cells , highlighting the importance of appropriate controls when studying variant effects.

How can TMEM216 antibodies help investigate ciliary signaling pathway dysregulation?

TMEM216 antibodies provide valuable tools for elucidating how this protein influences key signaling pathways, particularly in ciliopathies:

• RhoA activation analysis:

  • Use TMEM216 antibodies alongside RhoA activity assays (RBD pulldown)

  • Quantify active vs. total RhoA in control and TMEM216-deficient cells

  • Correlate TMEM216 expression with spatial distribution of active RhoA

• Dishevelled phosphorylation assessment:

  • Monitor Dvl1 phosphorylation status in relation to TMEM216 expression

  • Analyze pathway activation using phospho-specific antibodies

  • Investigate TMEM216-Dvl spatial relationships using co-immunostaining

• Actin cytoskeleton organization studies:

  • Examine co-localization of actin stress fibers and actin cross-linkers (e.g., filamin-A)

  • Quantify cytoskeletal changes in TMEM216-deficient cells

  • Analyze TMEM216's role in mediating Rho-dependent actin remodeling

• PCP pathway component analysis:

  • Investigate non-canonical Wnt signaling components in TMEM216 mutant contexts

  • Monitor ciliary localization of PCP proteins using co-immunostaining

  • Assess functional relationships through pharmacological manipulation

Research has established that loss of TMEM216 leads to hyperactivation of RhoA signaling and increased phosphorylation of Dishevelled 1 (Dvl1) . TMEM216-deficient cells also show mislocalization of RhoA to peripheral regions of the basal body and to basolateral cell-cell contacts . Additionally, MKS2 patient fibroblasts with TMEM216 mutations display abnormal co-localization of actin stress fibers and filamin-A in the cytoplasm .

These findings suggest TMEM216 acts as a negative regulator of RhoA and Dvl1 activation, with its loss potentially disrupting planar cell polarity signaling. TMEM216 antibodies can help further dissect these pathways by enabling precise spatiotemporal analysis of signaling components in various experimental contexts.

What considerations are important when using TMEM216 antibodies in developmental studies?

Using TMEM216 antibodies in developmental studies requires specific methodological considerations:

• Developmental stage selection:

  • Choose appropriate timepoints based on TMEM216 expression patterns

  • Consider that TMEM216 is expressed from early embryonic stages through adulthood

  • Design experiments around critical developmental windows for ciliogenesis

• Tissue processing optimization:

  • Adjust fixation protocols for embryonic versus adult tissues

  • Optimize antigen retrieval methods for developmental samples

  • Consider vibratome sectioning for better preservation of ciliary structures

• Cross-species antibody validation:

  • Verify antibody cross-reactivity with TMEM216 orthologs in model organisms

  • Test antibody performance in zebrafish, mouse, and human samples

  • Confirm specificity against species-specific knockout controls

• Expression pattern analysis:

  • Map TMEM216 distribution across developmental timepoints

  • Compare protein localization with mRNA expression data

  • Correlate expression patterns with developmental processes

Research has shown that TMEM216 is expressed in multiple organs during development, including the central nervous system, limb bud, kidney, and cartilage in human embryos . In zebrafish, tmem216 is widely expressed in multiple organs including the eye, pronephros, brain, liver, intestine, and muscle from 3 days post-fertilization (dpf) . Within the retina, expression is observed in all cell layers including the outer nuclear layer, inner nuclear layer, and ganglion cell layer .

For developmental studies, it's important to note that TMEM216 mRNA has been detected in freshly laid zebrafish eggs, 7-dpf larvae, and adult tissues including eye, brain, and skeletal muscle , suggesting roles throughout development and into adulthood.

What are common pitfalls in TMEM216 immunostaining and how can they be overcome?

Researchers working with TMEM216 antibodies may encounter several common immunostaining challenges:

• Low signal intensity issues:

  • Problem: Weak or barely detectable TMEM216 staining

  • Solutions:

    • Increase antibody concentration or incubation time

    • Try signal amplification systems (tyramide signal amplification, TSA)

    • Optimize antigen retrieval methods

    • Test alternative fixation protocols that better preserve epitopes

• High background challenges:

  • Problem: Non-specific staining obscuring true TMEM216 signal

  • Solutions:

    • Increase blocking duration and concentration

    • Test different blocking agents (BSA, milk, normal serum)

    • Add 0.1-0.3% Triton X-100 to washing buffers

    • Pre-absorb antibody against fixed negative control tissue

• Inconsistent ciliary labeling:

  • Problem: Variable detection of TMEM216 at ciliary structures

  • Solutions:

    • Standardize cell culture conditions and serum starvation protocols

    • Control for cell cycle stage and confluency

    • Use glutamylated tubulin as a stable marker for mature cilia

    • Consider cell polarization status on different substrates

• Antibody specificity concerns:

  • Problem: Uncertain whether staining represents true TMEM216 localization

  • Solutions:

    • Include TMEM216 knockout/knockdown controls in parallel

    • Perform peptide competition assays

    • Compare staining patterns with multiple antibodies against different epitopes

    • Correlate protein localization with mRNA expression patterns

Previous research successfully visualized TMEM216 at the base of primary cilia using antibodies raised against amino acids 81-90 . When optimizing TMEM216 immunostaining, researchers should consider that the protein strongly localizes to the base of cilia in organs like kidney containing ciliated cells , but may require careful optimization for detection in other tissues or cell types.

How can researchers address conflicting data about TMEM216 protein interactions?

When faced with conflicting data about TMEM216 protein interactions, researchers should implement a systematic troubleshooting approach:

• Interaction detection method comparison:

  • Test multiple complementary techniques:

    • Co-immunoprecipitation with reciprocal pulldowns

    • Proximity ligation assays for in situ detection

    • FRET/FLIM analysis for direct molecular interaction

    • Yeast two-hybrid or mammalian two-hybrid assays

• Interaction condition optimization:

  • Systematically vary experimental conditions:

    • Test different cell lysis buffers (varying detergent types/concentrations)

    • Compare native versus crosslinked samples

    • Evaluate the impact of calcium/magnesium concentrations

    • Consider protein post-translational modifications

• Protein domain analysis:

  • Map interaction interfaces through:

    • Truncation mutant series to identify binding domains

    • Site-directed mutagenesis of key residues

    • Peptide competition assays with synthesized domain fragments

    • In silico structural predictions to guide experimental design

• Context dependency investigation:

  • Analyze interaction variability across:

    • Different cell types and tissues

    • Various cellular states (proliferating vs. differentiated)

    • Different developmental timepoints

    • Disease-relevant conditions

Research has established that TMEM216 forms complexes with Meckelin through immunoprecipitation experiments where GFP-tagged TMEM216 was pulled down with antibodies to either N- or C-terminal portions of Meckelin, and the reciprocal IP experiment used α-GFP antibody to pull down Meckelin . TMEM216 is also part of the transition zone tectonic complex that includes multiple ciliopathy-associated proteins .

When addressing conflicting interaction data, consider that TMEM216's tetraspan transmembrane structure may facilitate complex formation with various membrane and cytosolic proteins, potentially in a context-dependent manner. Tetraspan proteins can act with Wnt receptors and participate in the formation of membrane domains that regulate signaling and sorting processes .